Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021” Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab Clinical and Molecular Hepatology.2025; 31(2): e200. CrossRef
Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules.
Citations
Citations to this article as recorded by
Correspondence to editorial on “CD36 Promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma” Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu Clinical and Molecular Hepatology.2026; 32(1): e75. CrossRef
Betaine supplementation prevents ethanol-induced disruption of intestinal tight junction integrity and liver inflammation in rats Karuna Rasineni, Ramachandran Rajamanickam, Sathish Kumar Perumal, Natalia A. Osna, Kusum K. Kharbanda Biochemical and Biophysical Research Communications.2026; 794: 152997. CrossRef
MyWayUp: A Digital Intervention for Alcohol Use Disorder in Patients With Alcohol‐Related Liver Disease—Results From an RCT Clara Oliveras, Mercè Balcells‐Oliveró, Ramón Bataller, Pol Bruguera, Noel Cabrera, Cristina Calomarde‐Gomez, Elsa Caballeria, Neus Freixa, Óscar Garcia‐Pañella, Jordi Gratacós‐Ginès, Pablo Guzman, Anna Hernández‐Rubio, Anna Lligoña, Lluisa Ortega, Martin Liver International.2026;[Epub] CrossRef
Heyndrickxia coagulans JF1 with potent ethanol-degrading capacity: In vitro screening and functional characterization Feiyu Yang, Xiangfei Li, Jing Sun, Xinyi Pang, Yonghong Hu, Chi Chen, Yingjian Lu, Fengxia Lv Food Bioscience.2026; 77: 108352. CrossRef
Naltrexone for Alcohol Use Disorder in Cirrhosis: Bridging the Gap in an Understudied Population Romina Vergara-Quispe, David Marti-Aguado, Ramón Bataller Journal of Clinical and Experimental Hepatology.2025; 15(2): 102509. CrossRef
Larsucosterol Moves Forward as a Treatment Contender for Alcohol-Associated Hepatitis Praveena Narayanan, Michael R. Lucey NEJM Evidence.2025;[Epub] CrossRef
New Developments on the Effects of Alcohol Use on Immunity, Inflammation and Organ Function: A Summary of the 2024 Alcohol and Immunology Research Interest Group (AIRIG) Meeting Madison M. Tschann, Vidula Vachharajani, Eileen M. Redmond, Andrew Hoisington, Sarah E. Cohen, Moses New-Aaron, Cristina Llorente, Janos Paloczi, Claudia R. Keating, Wiramon Rungratanawanich, Ellen L. Burnham, John J. Callaci, Preeti Raju, Weizhe Zhong, A Alcohol.2025;[Epub] CrossRef
Trabecular microcalli in lumbar vertebrae of adult men with alcohol-associated liver disease: Postmortem micro-computed tomography assessment Uros Andjelic, Marko Uzelac, Filip Filipovic, Mihailo Ille, Marija Djuric, Jelena Jadzic Srpski arhiv za celokupno lekarstvo.2025; 153(3-4): 146. CrossRef
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul Clinical and Molecular Hepatology.2025; 31(3): e273. CrossRef
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho Cardiovascular Diabetology.2025;[Epub] CrossRef
Physiological Mechanisms Vulnerable to Alcohol‐Induced Alterations: Role in Chronic Comorbidities Liz Simon, Kaitlin E. Couvillion, Meagan E. Donovan, Eden M. Gallegos, Flavia M. Souza‐Smith, Patricia E. Molina Comprehensive Physiology.2025;[Epub] CrossRef
PARP‑1 in liver diseases: Molecular mechanisms, therapeutic potential and emerging clinical applications (Review) Kaipeng Hu, Heng Tian, Shuxing Chen, Yuhan Liu, Ran Wei, Bangjie Chen, Yiwen Jia Molecular Medicine Reports.2025; 32(6): 1. CrossRef
Scutellarein attenuates alcohol-induced hepatocyte injury by modulating NF-κB and NRF2 signaling pathways Shuxia Shen, Minghua Cao, Ziqi Sui Medicine.2025; 104(39): e44506. CrossRef
Dietary and Lifestyle Risk Factors in Primary Sclerosing Cholangitis: In Search of Mechanistic Explanations and Health Improvement Ruslan A Mammadov, Henk P Roest, Luc JW van der Laan, Maikel P Peppelenbosch The Journal of Nutrition.2025; 155(12): 4087. CrossRef
A Novel Sesquiterpene from Callistephus chinensis Improves Alcohol-Induced Liver Disease by Regulating the AMPK/NF-κB Signaling Pathway and Gut Flora Bingxin Zhang, Ning Wang, Xiaoxu Chen, Nan Yang, Ying Zhao, Xiaoshu Zhang Molecules.2025; 30(22): 4371. CrossRef
The prevalence of obesity and metabolic consequences such as nonalcoholic fatty liver diseases (NAFLD) has become a crucial health problem. Lifestyle modifications, especially weight loss, effectively reduces liver injury in NAFLD patients. However, adherence to lifestyle changes is very low in the clinical setting. Bariatric surgery can improve metabolic components and cause long-term weight loss. Therefore, bariatric surgery could serve as an attractive treatment option for NAFLD patients. This review integrates data about the benefits of bariatric surgery on NAFLD but also describes the potential pitfalls.
Citations
Citations to this article as recorded by
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States Brian P. Lam, Jessica Bartholomew, Sherona Bau, HoChong Gilles, Andrea Keller, Ann Moore, Khalil Nader, Lisa Richards, Linda Henry, Zobair M. Younossi Journal of Clinical Gastroenterology.2025; 59(4): 298. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, Amerta Ghosh, Seema Gulati, Narendra Singh Choudhary, Deep Dutta, Praveen Sharma, Naval K. Vikram, Ashu Rastogi, Akash Shukla, Alpesh Goyal, Amit Gupta, Anand V. Kulkarni, Anil Chandra Anand, Anil Arora, A Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2025; 19(3): 103209. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Post-Metabolic Bariatric Surgery Cirrhosis and the Role of Liver Transplantation: A Report from a Referral Transplant Center Hamed Nikoupour, Erfan Sheikhbahaei, Alireza Shamsaeefar, Kourosh Kazemi, Mohammad Eslamian, Hamidreza Zefreh, Seyed Ali Malek-Hosseini, Saman Nikeghbalian Obesity Surgery.2025; 35(6): 2111. CrossRef
Comparative Analysis of the Incidence of Post-bariatric Cholelithiasis in Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Fernando de Barros, Enmanuel Compres Guichardo, Ana Beatriz Monteiro Fonseca, Leonardo Halamy Pereira, Daniel Alejandro Reyes Encalada Obesity Surgery.2025; 35(8): 3157. CrossRef
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid Cureus.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2025;[Epub] CrossRef
Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle Shanshan Liu, Yu Ji, Luyang Wei, Yiqiao Zhang, Linghang Zeng, Yiyang Min, Danyang Yin, Kun Liu, Chengjian Guan, Shumeng Liu, Huajing Yu, Zhongtao Zhang Nature Communications.2025;[Epub] CrossRef
Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes Aryan Shah, Amirhossein Mohammadi, Adeel Haq, David Walji, Boris Zevin Obesity Surgery.2025; 35(10): 4508. CrossRef
Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min Journal of Clinical Medicine.2025; 14(20): 7284. CrossRef
Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD Yujia Shi Hepatology International.2025;[Epub] CrossRef
Development and validation of a noninvasive score for at-risk metabolic dysfunction–associated steatohepatitis in individuals with obesity undergoing bariatric surgery Xin Huang, Tao Zhu, Shumin Li, Teng Liu, Shibo Lin, Hui Liang, Mingwei Zhong, Xitai Sun, Liyong Chen, Hao Bai, Zehua Zhao, Shujuan Lin, Xuehui Chu, Zhiyong Dong, Guangyong Zhang, Shaozhuang Liu Hepatology.2025;[Epub] CrossRef
Mid-term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-invasive Diagnosis Èlia Navarro-Masip, Núria Mestres, Marta Zorzano-Martínez, Blanca Salinas-Roca, Enric Sánchez, Carolina López-Cano, Fernando Herrerías, Mari Cruz de la Fuente, Maite Santamaría, Josep León-Mengíbar, Ana-Gloria Soler, Marta Bueno, Albert Lecube Obesity Surgery.2024; 34(3): 841. CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Bacteroides and NAFLD: pathophysiology and therapy Jun Zhang, Jing Zhou, Zheyun He, Hongshan Li Frontiers in Microbiology.2024;[Epub] CrossRef
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman Alimentary Pharmacology & Therapeutics.2024; 60(2): 167. CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
The Role of Preoperative Abdominal Ultrasound in the Preparation of Patients Undergoing Primary Metabolic and Bariatric Surgery: A Machine Learning Algorithm on 4418 Patients’ Records Mohamed Hany, Mohamed El Shafei, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Anwar Ashraf Abouelnasr, Moustafa R. Aboelsoud, Ehab Elmongui, Bart Torensma Obesity Surgery.2024; 34(9): 3445. CrossRef
Cytokeratin 18 in nonalcoholic fatty liver disease: value and application Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li Expert Review of Molecular Diagnostics.2024; 24(11): 1009. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients Álvaro Pérez-Rubio, Polina Soluyanova, Erika Moro, Guillermo Quintás, Iván Rienda, María Dolores Periañez, Andrés Painel, José Vizuete, Judith Pérez-Rojas, José V. Castell, Ramón Trullenque-Juan, Eugenia Pareja, Ramiro Jover Nutrients.2023; 15(14): 3187. CrossRef
First
Prev
